Taro Pharmaceutical Industries Ltd. (TARO) Short Interest Down 42.2% in December

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 869,027 shares, a drop of 42.2% from the November 30th total of 1,502,780 shares. Currently, 8.2% of the company’s stock are short sold. Based on an average daily volume of 126,816 shares, the days-to-cover ratio is presently 6.9 days.

Separately, BidaskClub raised shares of Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Thursday, September 28th.

Shares of Taro Pharmaceutical Industries (TARO) opened at $104.12 on Tuesday. Taro Pharmaceutical Industries has a 52 week low of $94.00 and a 52 week high of $128.46. The firm has a market cap of $4,178.63, a price-to-earnings ratio of 12.82 and a beta of 0.63.

Several institutional investors have recently added to or reduced their stakes in TARO. Wells Fargo & Company MN grew its position in shares of Taro Pharmaceutical Industries by 11.2% in the 2nd quarter. Wells Fargo & Company MN now owns 1,685 shares of the company’s stock valued at $189,000 after purchasing an additional 170 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Taro Pharmaceutical Industries during the 2nd quarter worth approximately $234,000. Russell Investments Group Ltd. raised its stake in shares of Taro Pharmaceutical Industries by 7.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,257 shares of the company’s stock worth $253,000 after purchasing an additional 156 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its stake in Taro Pharmaceutical Industries by 88.9% in the 3rd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 3,400 shares of the company’s stock valued at $383,000 after acquiring an additional 1,600 shares during the period. Finally, Highstreet Asset Management Inc. raised its stake in Taro Pharmaceutical Industries by 66.1% in the 3rd quarter. Highstreet Asset Management Inc. now owns 3,621 shares of the company’s stock valued at $408,000 after acquiring an additional 1,441 shares during the period. 13.44% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2018/01/09/taro-pharmaceutical-industries-ltd-taro-short-interest-down-42-2-in-december.html.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit